Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
2016 · Annals of the Rheumatic Diseases · 275 citations
https://doi.org/10.1136/annrheumdis-2015-207963